|

Breast Cancer Clinical Trials in New Jersey

143 recruiting studies across 53 cities

All Trials in New Jersey

Phase
Trial Phase Location
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast CancerPhase 1/2Basking Ridge
A Registry for People With T-cell Lymphoma—Basking Ridge
A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast CancerPhase 1Basking Ridge
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast CancerPhase 1Basking Ridge
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander PlacementPhase 4Basking Ridge
A Study of Blood Pressure Control During Cancer TreatmentPhase 2Basking Ridge
A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)—Basking Ridge
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell LymphomaPhase 2Basking Ridge
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast CancerPhase 2Basking Ridge
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast CancerPhase 2Basking Ridge
A Study of Language Interpretation Solutions for People With Breast CancerN/ABasking Ridge
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal MesotheliomaPhase 1Basking Ridge
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast CancerPhase 1Basking Ridge
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast CancerPhase 2Basking Ridge
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft TissueN/ABasking Ridge
A Study of Revaree Plus in People With Breast CancerPhase 4Basking Ridge
A Study of Romosozumab in People With Breast Cancer and OsteoporosisPhase 2Basking Ridge
A Study of SDX-7320 in Combination With Eribulin for People With Breast CancerPhase 2Basking Ridge
A Study of Skipping Radiation Therapy in People With Breast CancerN/ABasking Ridge
A Study of Surgery and Radiotherapy in People With Breast CancerPhase 2Basking Ridge
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast CancerPhase 3Basking Ridge
A Study of a Decision Tool for People Considering Breast Reconstruction SurgeryN/ABasking Ridge
A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With CancerN/ABasking Ridge
A Study of a Side Effects and Resource Navigation Program for People With CancerN/ABasking Ridge
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast CancerPhase 1Basking Ridge
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast CancerPhase 2Basking Ridge
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast CancerPhase 2Basking Ridge
A Study to Prevent and Improve Sexual Health Concerns for People With Breast CancerN/ABasking Ridge
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3Basking Ridge
Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer SurvivorsPhase 2Basking Ridge
Factors Associated With Breast Cancer Risks and Outcomes—Basking Ridge
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) ProtocolPhase 4Basking Ridge
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term RemissionPhase 2Basking Ridge
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of DiseasePhase 2Basking Ridge
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma—Basking Ridge
Lymphedema Surveillance Study—Basking Ridge
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized TrialN/ABasking Ridge
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors—Basking Ridge
Researching the Effect of Exercise on CancerN/ABasking Ridge
Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes—Basking Ridge
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations—Basking Ridge
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast CancerPhase 2Basking Ridge
Study of Aerobic Training for People Receiving Treatment for Breast CancerPhase 2Basking Ridge
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your JobN/ABasking Ridge
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase 3Basking Ridge
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3Belleville
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-AdjustmentPhase 4Belleville
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationPhase 3Belleville
RADIANT: Pre-op Radiation With Abemaciclib and LetrozolePhase 1Belleville
E-Mindfulness Approaches for Living After Breast CancerPhase 3Berkeley Heights
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyPhase 3Camden
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 3Camden
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesPhase 1/2Camden
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3Camden
Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes—Camden
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3Camden
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsPhase 3Camden
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2Camden
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerPhase 3Camden
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3Camden
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerN/ACamden
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/ACape May Court House
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 3Cherry Hill
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 3Cherry Hill
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPhase 3Cherry Hill
Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before SurgeryN/ACherry Hill
A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerPhase 1East Brunswick
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 1East Brunswick
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerPhase 2East Brunswick
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)Phase 3East Brunswick
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerPhase 3East Brunswick
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsPhase 1East Brunswick
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsPhase 1East Brunswick
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseasePhase 3East Brunswick
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—East Brunswick
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsPhase 1East Brunswick
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid TumorsPhase 1/2East Brunswick
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositivePhase 2/3East Brunswick
SLV-154 Treatment of Advanced CancersPhase 1East Brunswick
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3East Brunswick
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerPhase 2East Brunswick
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPhase 3Elizabeth
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast CancerPhase 2Elizabeth
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 TargetedPhase 2Elizabeth
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast CancerPhase 2Elizabeth
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—Englewood
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—Englewood
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentPhase 2Englewood
The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyPhase 3Englewood
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Phase 3Flemington
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPhase 2Flemington
A Study of DB-1310 in Advanced/Metastatic Solid TumorsPhase 1/2Florham Park
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast TumorsN/AFlorham Park
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies—Florham Park
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerPhase 3Florham Park
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerPhase 1/2Freehold
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Phase 3Hackensack
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Phase 3Hackensack
A Phase 1 Study of LNCB74 in Advanced Solid TumorsPhase 1Hackensack
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsPhase 1Hackensack
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerPhase 3Hackensack
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPhase 1/2Hackensack
A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsPhase 1Hackensack
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsPhase 1/2Hackensack
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPhase 1/2Hackensack
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsPhase 1/2Hackensack
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H MutationPhase 1Hackensack
A Study of LY4175408 in Participants With Advanced CancerPhase 1Hackensack
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationPhase 3Hackensack
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Phase 3Hackensack
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 3Hackensack
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsPhase 1/2Hackensack
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Phase 3Hackensack
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)—Hackensack
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)Phase 1/2Hackensack
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPhase 3Hackensack
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast CancerPhase 1/2Hackensack
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During SurgeryPhase 1/2Montvale
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyPhase 2Morristown
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3Morristown
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsPhase 1New Brunswick
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 1New Brunswick
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationPhase 1New Brunswick
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerPhase 1/2New Brunswick
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPhase 1New Brunswick
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPhase 2New Brunswick
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast CancerN/ANew Brunswick
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung CancerPhase 1New Brunswick
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerPhase 2New Brunswick
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—New Brunswick
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)Phase 1/2New Brunswick
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast CancersN/ANewark
Rutgers University Study of the Genetics of Breast Cancer.—Piscataway
A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical TrialsN/APlainsboro
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer—Plainsboro
Phase 1 Study of CLR 125 in Triple Negative Breast CancerPhase 1Princeton
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsPhase 1Princeton
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense BreastsN/ASewell
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsPhase 2Summit
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerPhase 3Summit
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs—Totowa
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic TherapyN/AVoorhees Township
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast CancerPhase 2Voorhees Township

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.